Study Overview: This research focuses on people with a condition called neovascular age-related macular degeneration (nAMD). nAMD is an eye disease where unusual blood vessels grow under the retina, which can lead to vision loss. Ixo-vec, a gene therapy, aims to treat nAMD and reduce the need for frequent eye injections. In this study, participants will receive a single injection of Ixo-vec to see if it works as well as the current treatment.
- Study Length: The main results will be checked around Weeks 52 and 56 after treatment.
- Visits Required: Participants will need to attend multiple visits for monitoring their safety and treatment effectiveness.
- Eligibility: Participants must be over 50, with nAMD in one eye, and meet other health criteria.
Participants should be willing to follow study guidelines and attend all scheduled visits. There are also some health conditions and treatments that might exclude a person from participating. Overall, this study hopes to find a better way to treat nAMD and maintain vision in older adults.
How understandable was the trial content above?
Hard to understand
Easy to understand